На главную
Результаты поиска “Hormone receptor positive breast cancer therapy”
Hormone Receptor-Positive Breast Cancer
 
02:30
Breastlink founder Dr. Link, author of “The Breast Cancer Survival Manual,” explains why drugs like Tamoxifen and aromatase inhibitors reduce a woman’s risk of developing breast cancer. When researches began sequencing cancer genes in 2003 and 2004, they discovered that cancer wasn’t a homogenous disease. There were variations and they eventually divided cancer into subtypes: triple negative (15% of breast cancer), HER2 amplified type (12-15% of breast cancer), and hormone receptor positive, also known as the luminal cancer (over 70% of breast cancer). Luminal cancer cells have estrogen and progesterone receptors on their surface and have to receive these hormones in order to survive. To prevent these tumors from getting estrogen, doctors prescribe Tamoxifen, which blocks the estrogen receptors and kills the cell. After a woman goes into menopause and her ovaries stop producing estrogen, the tumor can still receive estrogen from the adrenal gland. Aromatase inhibitors are used to block adrenal estrogen. For more information about Breastlink and breast cancer, visit our website: www.breastlink.com
Просмотров: 3476 Breastlink Orange
Hormone Receptor Positive Breast Cancer
 
02:57
All breast tumors are tested to see if they are hormone sensitive. Those tumors that are hormone sensitive will typically respond to anti-estrogen treatments. In this video, you will learn about hormone-sensitive breast cancer.
Просмотров: 1786 Dr. Susan Love Research Foundation
Estrogen Receptor Positive Breast Cancer. ER+. What is it?
 
04:55
ER positive breast cancer means that the cancer cells grow and reproduce fast in response to the hormone estrogen. The diagnosis is based on the results of Immunohistochemistry assay. Assay is used to show whether or not the cancer cells have hormone receptors on their surface. Why is it important? When Estrogen gets attached to the receptor, it’s a signal to our DNA: start to grow and reproduce. (1)The more receptors cancer calls have, the stronger the signal. (2)The more Estrogen there is in the blood stream, the stronger the signal to the DNA. Hormone receptor status is important because oncologist will decide whether the cancer is likely to respond to hormonal therapy. Hormonal therapy includes medications that (1) block estrogen receptor, so Estrogen cannot sit there and send the signal to the DNA: grow and reproduce or (2) lower the amount of estrogen in the body. As a Naturopathic Physician I make sure that my patients do not consume estrogen-like substances. My specialty is: reduction of all types of cancer. Food, water and cosmetics, all should be free of chemicals Stay healthy Dr. V Waks
Просмотров: 2230 Doctor Veronica
Hormone Receptor-Positive and HER2-Positive Breast Cancer: A Medical Update
 
01:08:15
Featuring Sara Hurvitz, MD, FACP, learn about the use of targeted therapies for early-stage, hormone receptor-positive and HER2-positive breast cancer, explore how these medicines reduce risk of recurrence and how they may be used before and after surgery.
Просмотров: 11859 Living Beyond Breast Cancer
Adjuvant Hormonal Therapy for Estrogen Receptor Positive Early Stage Breast Cancer
 
04:54
This video clip will review hormonal therapy options for both pre- and post-menopausal women with estrogen receptor positive, early stage breast cancer. The risks and benefits of Tamoxifen and the Aromatase Inhibitors (anastrozole, letrozole, exemestane) are discussed.
Просмотров: 3140 Mayo Clinic
Advancements in Estrogen Receptor–Positive Breast Cancer
 
09:47
Ingrid A. Mayer, MD, MSCI, and Hope S. Rugo, MD, discuss the role of targeted therapies in the treatment of estrogen receptor–positive breast cancer.
Просмотров: 3209 OncLiveTV
Hormone Receptor-Positive Advanced Breast Cancer: Challenges and New Treatment Options
 
01:25:42
This webcast provides expert insight on management strategies for patients with HR-positive breast cancer. Over a review of several cases, the faculty will provide their assessments, as well as additional details on current abemaclib, ribociclib, palbociclib, and faslodex studies, everolimus and NSABP B 42, breast cancer index and other biomarkers. The webcast is moderated by Dr. Jame Abraham of the Cleveland Clinic. Visit http://www.ccfcme.org/tumorboard to claim CME credit or learn more about the Biologic Therapies VII series. Interested in related CME education? Visit http://www.ccfcme.org
Просмотров: 84 ClevelandClinicCME
A Discussion on Hormone Receptor-Positive Breast Cancer and the Latest in Surgical Management
 
01:15:31
The Breast Cancer Issues Conference is a place to discuss topics covering the latest in breast cancer research and treatment, risk reduction and quality of life issues with leading researchers and experts. Brought to you by Susan G. Komen Oregon and SW Washington.
Просмотров: 48 Susan G. Komen Oregon & SW Washington
Advanced Hormone Receptor-positive Breast Cancer
 
20:13
Filmed on location in Las Vegas during the 21st Annual NOCR Meeting, this webcast is part of a series that provides expert discussions from physicians and researchers from around the USA reviewing current standards of management and analyzing the most important new data that has the potential to modify treatment guidelines. In this presentation, Dr. William Gradishar expounds upon the latest updates in the treatment of advanced hormone receptor-positive breast cancer. © 2015 Imedex, LLC.
Просмотров: 288 ImedexCME
Treatment Overview: ER-positive Breast Cancer
 
04:10
Adam M. Brufsky, MD, PhD, and Lynn Acierno, BSN, RN, OCN, RN-BC, discuss common considerations of patients and their healthcare professionals in the treatment of hormone receptor positive breast cancers. View more at http://curetoday.com/ CURE: Combining science and humanity to make cancer understandable.
Просмотров: 34 curetoday
Treatment of ER+ Breast Cancer
 
03:49
SERM = SELECTIVE estrogen receptor modulator, not "SPECIFIC" estrogen receptor modulator, which is what i said in this video. Sorry for the confusion!
Просмотров: 842 YT Productions
Hormonal therapy in breast cancer
 
20:17
This video describes therapy with anti-estrogens medications in breast cancer.
Просмотров: 22537 charlottecancer
Treatment Strategies in ER-Positive Breast Cancer
 
01:36
Adam Brufsky, MD, discusses tamoxifen therapy and the use of genomic assays in estrogen-receptor positive metastatic breast cancer. For more expert insight, visit http://www.onclive.com/insights/evolution-metastatic-breast-cancer
Просмотров: 352 OncLiveTV
Hormone Receptor Positive, HER2- Breast Cancer Clinical Trial
 
04:25
A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016. http://www.bigtencrc.org
Просмотров: 225 Big Ten Cancer Research Consortium
Risk Stratification of Patients with Hormone-Receptor Positive Breast Cancer
 
02:51
Peter Schmid, Professor of Cancer Medicine and Clinical Director of the St. Bartholomew Breast Cancer Centre, UK, explores how risk stratification is performed in clinical practice and how treatment strategies are decided for patients with hormone-receptor positive breast cancer. Q1. How is risk stratification performed in clinical practice, and how do you decide if a patient with hormone-receptor positive breast cancer is suited for endocrine monotherapy, targeted combination therapy or chemotherapy? Q2. How can this decision-making process be made less subjective in the future? Support: This video was supported by AstraZeneca.
Просмотров: 15 Touch Medical Media
Adjuvant Therapy for ER+/HER2+ Breast Cancer
 
06:34
Panelists Michael Untch, MD; Adam M. Brufsky, MD, PhD; Hope S. Rugo, MD; and Joyce A. O’Shaughnessy, MD, discuss sequencing of a HER2-targeted TKI and HER2-targeted monoclonal antibody, and lessons learned from the GeparQuinto and ExteNET trials in ER-positive HER2-positive breast cancer.
Просмотров: 296 OncLiveTV
Adjuvant Therapy in Early-Stage ER-Positive, HER2-Negative Invasive Breast Cancer
 
10:59
Dr. Hope Rugo shares her experience on the recommended treatment approach for ER-positive, HER2-negative breast cancer patients. She comments on what is the expected benefit of adjuvant chemotherapy and endocrine therapy in luminal breast cancers and mentions that one of the greatest challenges is to understand the heterogeneity of the tumor. She also provides interesting comments on the use of criteria like tumor grade and size to select the patients for adjuvant chemotherapy as well as the usage of IHC markers such hormone receptors ER-positive, PR and Growth Factor Receptor HER2 to identify patients for chemotherapy. Finally, she speaks about tools such Adjuvant! Online and Predict and debates if these tools could be used to select luminal breast cancer patients confidently for adjuvant chemotherapy. _______________________________________________________ Hope Rugo, MD, is the Clinical Professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology and Clinical Trials Education at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.
Просмотров: 7496 Genomic Health, Inc.
Hormone Positive (ER+/PR) MBC - Dr. Katie Reeder Hayes - 2014 MBCN Conference at UNC
 
44:43
Current diagnosis, treatment and management of Hormone sensitive metastatic breast cancer also called ER+/PR+ or ER+/PR- disease.
Просмотров: 1178 Metastatic Breast Cancer Network (MBCN)
Hormone Receptor Positive Disease: New Developments
 
35:27
Lecture by Martine J. Piccart-Gebhart, M.D., Ph.D. This podcast highlights important outstanding issues with respect to hormone receptor positive disease, including clinical thresholds for considering chemotherapy, opportunities to further tailor endocrine therapy, distinguishing characteristics of luminal A and luminal B tumors, and novel tumor markers.
Просмотров: 867 TheOncologistJournal
Breast Cancer | Dr. Tony Talebi discusses "Estrogen Receptor Positive Breast Cancer".
 
12:59
Dr. Tony Talebi discusses Estrogen Receptor Positive Breast Cancer with Dr. Lippman. For further discussion please visit http://www.HemOnc101.com Breast cancer is the most common female cancer in the US. Important risk factors for breast cancer are age, gender, reproductive history, hormonal factors, and family history. Although a family history of breast and/or ovarian cancer is common in patients diagnosed with breast cancer, less than ten percent of all breast cancers are associated with genetic mutations. Assay of hormone receptors (estrogen [ER] and progesterone [PR] receptors) is an important component of the pathologic evaluation of breast cancer, for both prognostic and predictive purposes, as patients with hormone receptor-positive tumors benefit from the addition of endocrine treatments. The treatment of early stage breast cancer includes the treatment of locoregional disease with surgery, radiation therapy, or both, and the treatment of systemic disease with one or a combination of chemotherapy, endocrine therapy, or biologic therapy. Here, Dr. Tony Talebi discusses the general concepts of what is estrogen receptor positive breast cancer with world renowned breast cancer expert Dr. Marc Lippman, professor and chairman of the department of medicine at the University of Miami. Dr. Marc Lippman pioneered the use of tamoxifen in estrogen receptor positive breast cancer with his early research while at the National Cancer Institute which revolutionized the treatment of breast cancer. The discussion includes symptoms, diagnosis, staging, genetic implications, surgery, radiation therapy, Oncotype DX testing, hormonal therapy including tamoxifen and aromatase inhibitors and chemotherapy for breast cancer. Dr. Marc Lippman credentials: Certifications American Board of Internal Med-Medical Oncology American Board of Internal Medicine American Bd of Int Med-Endocrinology Diabetes & Metabolism Specialties Hematology/Oncology - Internal Medicine Internal Medicine Roles Interim Deputy Director, Sylvester Comprehensive Cancer Center Professor and Chairman Biography Marc E. Lippman, M.D. was named the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard M. Miller School of Medicine, and was named Chairman of the Department of Medicine in May 2007. Previously Dr. Lippman was the John G. Searle Professor and Chair of Internal Medicine at the University of Michigan, Ann Arbor, Michigan. From 1988 through 1999 Dr. Lippman was Professor of Medicine and Pharmacology, and Chair, Department of Oncology at Georgetown University in Washington, D.C., and served as Director of the Lombardi Cancer Center at Georgetown University Medical Center. From 1978 through 1990 he was Clinical Professor of Medicine and Pharmacology, Uniformed Services, University of the Health Sciences. Dr. Lippman served as Head of the Medical Breast Cancer Section, Medicine Branch, at the National Institute of Health. He was a Senior Investigator at the National Cancer Institute of the National Institute of Health. Dr. Lippman completed a Fellowship in Endocrinology at Yale Medical School in New Haven, CT from 1973-1974. In addition, he was Clinical Associate at the National Cancer Institute from 1970-1971 and Clinical Associate at the Laboratory of Biochemistry of the National Cancer Institute of the National Institute of Health. From 1970 to 1988 he served as an Officer and Medical Director of the United States Public Health Service. Dr. Lippman completed his residency on the Osler Medical Service, John Hopkins Hospital, in Baltimore, Maryland from 1968-1970. A native of New York, Dr. Lippman received his Bachelor's Degree from Cornell University, Magna Cum Laude, and medical school degree at Yale Medical School in New Haven, CT where he was elected to AOA. Dr. Lippman is widely known for his research in breast cancer. Throughout his illustrious career he has received numerous awards including Mallinckrodt Award of the Clinical Radioassay Society in 1978; the Commendation Medal USPHS in 1982; Meritorius Service Medal, USPHS in 1987; Clinical Investigator Award, American Federation for Clinical Research in 1985; D.R. Edwards Lecture and Medal, Tenovus Institute, Wales 1985; Plenary Lecturer, British Association of Cancer Research in 1987; Gosse Lecture, Dalhuosie University, Halifax Nova Scotia in 1987; the American Cancer Society.
Просмотров: 2127 Tony Talebi
Anastrozole and Fulvestrant in Hormone Receptor-Positive Breast Cancer
 
05:50
A commentary by Dr. William J. Gradishar and Dr. Hope S. Rugo on fulvestrant and anastrozole as first-line therapy in hormone receptor-positive breast cancer
Просмотров: 937 MDedge
Anti-Estrogen Therapy and Breast Cancer Recurrence
 
01:06
http://www.dailyrxnews.com/extending-anti-estrogen-therapy-reduced-breast-cancer-recurrence-massachusetts-general-hospital After fighting through chemotherapy, radiation or other treatments, the recurrence of cancer can be a bummer. But a new approach to hormone therapies might give doctors and patients a leg up. Research presented at the American Society of Clinical Medicine indicated that extending the length of anti-estrogen hormone therapy decreased the risk of breast cancer recurrence. A type of breast cancer known as hormone receptor-positive breast cancer is driven by the hormones estrogen, progesterone or both. As part of the treatment, women with this kind of breast cancer typically receive medications called aromatase inhibitors, which help reduce levels of estrogen. Many patients also receive a medication called tamoxifen which also reduces estrogen.
Просмотров: 406 dailyRx
Breast Cancer Pathogenesis
 
04:40
Breast cancer is the most common cancer worldwide, and the second leading cause of cancer death.Breast cancer cells have receptors on their surface and in their cytoplasm and nucleus. Chemical messengers such as hormones bind to receptors, and this causes changes in the cell. Breast cancer cells may or may not have three important receptors: estrogen receptor (ER), progesterone receptor (PR), and HER2. ER+ cancer cells depend on estrogen for their growth. Untreated, HER2+ breast cancers are generally more aggressive than HER2- breast cancers. Cells that do not have any of these three receptor types are called triple-negative, although they frequently do express receptors for other hormones, such as androgen receptor and prolactin receptor. It is important to understand the aetio-pathogenesis of this common disease, which is associated with high morbidity and mortality, especially if not detected early. Therefore, the roles of early screening in high risk or susceptible individuals, as well as proper surveillance of treated cases in order to detect recurrence at the early stages have been advocated.
Просмотров: 5281 Proteinlounge
BREAST CANCER: ESTROGEN RECEPTORS
 
02:06
BREAST CANCER: ESTROGEN RECEPTORS
Просмотров: 7069 Walter Jahn
Treatment for Early-Stage ER+ Breast Cancer
 
07:04
Hope S. Rugo, MD, and Ruth O’Regan, MD, discuss adjuvant and neoadjuvant endocrine therapy as treatment for early-stage estrogen receptor(ER)–positive breast cancer.
Просмотров: 364 OncLiveTV
Statin use & cholesterol in estrogen receptor-positive breast cancer treated with endocrine therapy
 
05:48
Signe Borgquist, MD, PhD and Associate Professor at Lund University discusses Cholesterol, Cholesterol Lowering Medication Use and Breast Cancer Outcomes in the BIG 1-98 Study at the 38th Annual San Antonio Breast Cancer Symposium 2015. MDLinx Conference Coverage - 38th Annual San Antonio Breast Cancer Symposium 2015: http://www.mdlinx.com/oncology/conference-interview/38th-annual-san-antonio-breast-cancer-symposium-sabcs-/66512 MDLinx: http://www.mdlinx.com/ Smartest Doc & Board Exam Prep: http://www.thesmartestdoc.com/ M3 USA: http://usa.m3.com/ Follow MDLinx: Facebook - https://www.facebook.com/MDLinx Twitter - https://twitter.com/MDLinx Google+ - https://plus.google.com/+Mdlinx/
Просмотров: 154 MDLinx
Breast Cancer Neoadjuvant Chemotherapy: For Patients
 
14:51
We teach you about the benefits of neoadjuvant chemotherapy. Chemotherapy before surgery, rather than afterwards, may offer distinct advantages in your unique breast cancer situation. VISIT THE BREAST CANCER SCHOOL FOR PATIENTS: http://www.breastcancercourse.org LIST OF QUESTIONS FOR YOUR DOCTORS: http://www.breastcancercourse.org/breast-health-updates-latest-videos/ FOLLOW US: Facebook: https://www.facebook.com/Breast-Cancer-School-for-Patients-958519147618444/ ___________________________________ Questions for your Breast Surgeon and Medical Oncologist: 1. Do you know now, before surgery, if I will need chemotherapy? 2. If “yes,” should we consider “Neoadjuvant Chemo” before surgery? 3. What are the benefits of Neoadjuvant Chemotherapy? 4. Isn’t Neoadjuvant Chemo recommended more now? 5. Do my receptors suggest I will need chemotherapy? 6. Do I have cancer in my axillary nodes? 7. Will you ultrasound my axillary lymph nodes today? 8. What is Neoadjuvant Chemotherapy? Neoadjuvant chemotherapy is when chemotherapy is given before surgery, not afterwards. Most never require chemotherapy. But if chemotherapy is needed, there can be specific advantages to neoadjuvant chemotherapy. This approach is a “cutting edge” trend in sophisticated breast cancer care. If your breast biopsy “receptor pattern” suggests you need chemotherapy, it is important for you to inquire about the possible benefits of neoadjuvant chemotherapy with your breast surgeon. If cancer is detected in your lymph nodes before surgery, you may also benefit from neoadjuvant chemotherapy. Learn more about receptors and chemotherapy with our video lesson “My Tumor Receptors” (here). When is chemotherapy generally needed? If needed, chemotherapy is most commonly given after surgery (“adjuvant” chemo) for invasive breast cancer. It is a more intense cancer treatment than hormonal therapy. Only a minority of breast cancer patients will ever need chemotherapy. These complex decisions are ones you will make with your medical oncologist and breast surgeon. You will make better treatment choices when you are well informed about chemotherapy before you meet your breast surgeon and medical oncologist. Would I benefit from “Neoadjuvant Chemo?” What is often overlooked are the benefits of offering neoadjuvant chemotherapy for appropriate “Early-Stage” breast cancer. The decision to consider neoadjuvant chemotherapy always begins with your breast surgeon. You and your breast surgeon will choose the initial direction of your entire breast cancer treatment plan. You must address this treatment option before surgery to benefit from neoadjuvant chemotherapy. Some breast surgeons do not yet embrace neoadjuvant chemotherapy for early stage cancers. Do not be afraid to ask. This is a very important question. The Potential Benefits of Neoadjuvant Chemo: *Begin life-saving chemotherapy earlier *Reduce the need for a mastectomy *Improve cosmetic outcomes with a lumpectomy *Reduce the need for an “Axillary Dissection” *Allow more time for BRCA genetic testing *More time to think about “lumpectomy vs. mastectomy” *Shows your cancer team if the chemo is working *Can eliminate all cancer cells before surgery in some *Reduce the need for radiation after a mastectomy Who may benefit from Neoadjuvant Chemo: We list below a few of the criteria important in deciding if neoadjuvant chemotherapy is an option for someone who has yet to undergo breast cancer surgery. Your Breast biopsy “Tumor receptors” reveal *“HER2-positive” receptors *“Triple Negative” receptors *Estrogen receptor negative OR: *Cancer is found in the Axillary Nodes before surgery *A tumor larger than 5 centimeters *Diagnosis is inflammatory breast cancer What “Receptor Patterns” suggest Neoadjuvant Chemo? HER2-Positive Receptor (HER2+) tumors are incredibly responsive to chemotherapy when paired with new breakthrough drugs that target these cancers, such as Herceptin and Perjeta. The same holds true if a HER2-positive tumor is also ER positive. “Triple Negative” (ER-)(PR-)(HER2-) tumors are also fast growing tumors that are usually treated with a specific chemotherapy regimen. These tumors are not responsive to hormonal therapy, but can be very sensitive to chemotherapy. Visit our “Triple Negative Breast Cancer“ video lesson (here). Estrogen Receptor Negative (ER-) tumors do not respond to anti-estrogen oral medications that are essential for treating estrogen receptor positive (ER+) tumors. Quite simply, patients with ER negative tumors will benefit from chemotherapy. Why does “Inflammatory Breast Cancer” mean Neoadjuvant Chemo? If you have been diagnosed with inflammatory breast cancer, the first step is always neoadjuvant chemotherapy before surgery. This type of cancer has a high likelihood of spreading to the lymph nodes and other parts of the body. Starting chemotherapy as soon as possible is essential to curing this aggressive breast cancer.
Просмотров: 135 Breast Cancer School for Patients
Which First Line Breast Cancer Therapy Is Right for Me
 
08:32
Which First-Line Breast Cancer Therapy Is Right for Me. Knowing where to turn next with your breast cancer treatment can be a tough decision. But understanding the different types of therapies can help ensure you know what’s best for you. Hormone and targeted therapies. The first-line treatment for advanced hormone receptor-positive (estrogen receptor-positive or progesterone receptor-positive) breast cancer is usually hormone therapy. Tamoxifen is generally the first option for premenopausal women. If you’re post-menopausal, you’ll likely try letrozole (Femara) or fulvestrant (Faslodex) first. Side effects of hormone therapy vary with each drug, but can include: *hot flashes and night sweats. *vaginal dryness. *loss of sex drive. *mood swings. Hormone therapies can also increase your risk of blood clots, stroke, and bone loss. Two targeted therapies for postmenopausal women with advanced hormone receptor-positive/HER2-negative breast cancer are: *Palbociclib (Ibrance), which is used in combination with an aromatase inhibitor. Side effects may include nausea, mouth sores, hair loss, fatigue, and diarrhea. This medication may raise your risk for infection. *Everolimus (Afinitor), which is used in combination with exemestane (Aromasin). It’s generally reserved for use after letrozole or anastrozole (Arimidex) have failed to control the cancer. Side effects can include shortness of breath, cough, and weakness. This medication can increase the risks of infection, high blood lipids, and high blood sugar. Careful monitoring of the blood is necessary. Targeted therapies for HER2-positive breast cancer include: *trastuzumab (Herceptin). *pertuzumab (Perjeta). *ado-trastuzumab emtansine (Kadcyla). *lapatinib (Tykerb). Some of these may be more effective when used in combination with chemotherapy. Most hormonal and targeted therapies are available in pill form. If side effects get overwhelming, or your cancer continues to progress while taking hormonal or targeted therapy, changing drugs is a good strategy. If you’ve already done that and cancer is still progressing, you may have to switch to chemotherapy alone. Chemotherapy. Chemotherapy drugs are designed to kill fast-growing cells, which is why they’re so effective in destroying cancer. But there are other fast-growing cells in your body that can be damaged in the process, including: *hair follicles. *cells in your bone marrow that help form blood. *cells in your mouth, digestive tract, and reproductive system. All Photos Licensed Under CC Source : www.pexels.com www.pixabay.com www.commons.wikimedia.org
Просмотров: 5812 Best Natural Cures
HER2 Positive Breast Cancer: Everything You Must Know
 
13:08
We teach you why HER2-positive breast cancers are more threatening and educate you about new therapies such as targeted immunotherapy and neoadjuvant chemotherapy. VISIT THE BREAST CANCER SCHOOL FOR PATIENTS: http://www.breastcancercourse.org LIST OF QUESTIONS FOR YOUR DOCTORS: http://www.breastcancercourse.org/breast-health-updates-latest-videos/ FOLLOW US: Facebook: https://www.facebook.com/Breast-Cancer-School-for-Patients-958519147618444/ _____________________________ Questions for your Breast Surgeon and Medical Oncologist: 1. What is HER2-Positive breast cancer? 2. Will I need Chemo and Targeted Therapy? 3. What are the benefits of Neoadjuvant Chemo? 4. Isn’t Neoadjuvant Chemo recommended more now? 5. Should I consider a Clinical Trial? 6. What is “HER2-Positive” breast cancer? “HER2-Positive” breast cancers are fast growing tumors that more frequently spread beyond the breast to other parts of the body. Because of this, they are a bigger threat to your life than most other types of cancers with different receptor patterns. These cancers are called “HER2-positive” because they have too many HER2 protein receptors on their surface. These tiny proteins act like “light switches” to turn cancer cell growth “on.” Chemotherapy, combined with new, “targeted” drugs, are very effective against HER2-positive breast cancer and are a leap forward in breast cancer care. Your Breast Surgeon will know your “receptor pattern” within days after your initial breast biopsy. These results are often not communicated to you early on in your decision process. Although only 20% of breast cancers are “HER2-positive,” it is imperative that you specifically ask your surgeon immediately, and well before surgery, “What are my receptor results?” Take our lesson on “My Tumor Receptors” to learn more. Treated with Chemo and “Targeted Therapy” HER2 Receptor Positive (HER2+) tumors are incredibly responsive to chemotherapy when paired with new breakthrough drugs that target these cancers, such as Herceptin and Perjeta. The same holds true if a HER2+ tumor is also Estrogen Receptor positive (ER+). HER2+ tumors are more aggressive cancers, but we now can treat them more effectively, than in the past, with chemotherapy and “targeted immunotherapy” drugs that are designed to destroy them. Everyone with a HER2+ tumor larger than 5mm (1/4 inch) and in good health is considered for chemotherapy and targeted therapy. Unfortunately, studies have shown that many patients are not offered these standard of care, life-saving “targeted drugs” along with chemotherapy. You will make better treatment choices when you are well informed about HER2 therapies before meeting with your medical oncologist. You must inquire about Herceptin, Perjeta, and other “anti-HER2 drugs” that may be of benefit to you. Ask about the benefits of “Neoadjuvant Chemo” What is often overlooked are the benefits of offering neoadjuvant chemotherapy for patients with HER2-Positive, “Early-Stage” (1 & 2) breast cancers. There are distinct advantages (listed below) to having chemotherapy before surgery instead of afterwards. The decision to consider neoadjuvant chemotherapy always begins with your breast surgeon. Breast surgeons choose the initial direction of your entire breast cancer treatment plan. You must address this “cutting edge” treatment option well before surgery to benefit from neoadjuvant chemotherapy. Do not be afraid to ask. This is a very important question. Learn more about “Neoadjuvant Chemotherapy“ by taking our video lesson on the topic. The Potential Benefits of Neoadjuvant Chemo: *Begin life-saving chemotherapy earlier *Reduce the need for a mastectomy *Improve lumpectomy cosmetic outcomes *Reduce the need for an “Axillary Dissection” *Allows more time for BRCA genetic testing *More time to think about “lumpectomy vs. mastectomy” *Shows your cancer team if the chemo is working *Can possibly eliminate all cancer cells before surgery *Reduces the need for radiation after a mastectomy Ask if you might benefit from a Clinical Trial. New therapies must be studied in clinical trials to make sure they are safe and effective at treating breast cancer. HER2-positive breast cancers are currently the focus of intense clinical research. New drug treatments are rapidly being developed for this aggressive cancer. Less than 5% of all patients with breast cancer participate in clinical trials. Patients with cancer willing to participate in clinical trials are essential for the advancement of breast cancer care. Ask your medical oncologist if they offer or recommend you participate in a clinical trial for your unique breast cancer situation. Learn more about “Clinicial Trials“ at the Breast Cancer School for Patients.
Просмотров: 1841 Breast Cancer School for Patients
PALOMA-3: Palbociclib plus fulvestrant in hormone receptor-positive advanced breast cancer
 
03:02
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill, NC, discusses the results of the double-blind, phase 3 PALOMA-3 trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.
Просмотров: 515 European Medical Group
Letrozole vs observation for HR positive breast cancer
 
04:33
Visit http://www.ecancer.org for more Dr Zdenkowski (University of Newcastle, Newcastle, Australia) talks to ecancertv at ASCO 2015 about the final analysis of a randomised comparison of letrozole versus observation as late reintroduction of adjuvant endocrine therapy (AET) for postmenopausal women with hormone receptor positive breast cancer after completion of prior AET.
Просмотров: 811 ecancer
New breast cancer drug study results are promising.
 
02:52
Researchers are encouraged by the early results for patients using Z-endoxifen. The potent derivative of the drug tamoxifen was given to women with estrogen receptor positive metastatic breast cancer, the most common form of breast cancer in women whose disease has spread. The phase I study demonstrated endoxifen shows promise for patients whose cancer had continued to progress with standard estrogen therapies, including tamoxifen.
Просмотров: 1034 Mayo Clinic
Breast Cancer Receptors: Learn What You Need to Know
 
08:26
We teach you to about breast cancer tumor receptors and why they are important in your breast cancer treatment. Chemotherapy and hormonal therapy are based on your receptor pattern. VISIT THE BREAST CANCER SCHOOL FOR PATIENTS: http://www.breastcancercourse.org LIST OF QUESTIONS FOR YOUR DOCTORS: http://www.breastcancercourse.org/breast-health-updates-latest-videos/ FOLLOW US: Facebook: https://www.facebook.com/Breast-Cancer-School-for-Patients-958519147618444/ _________________________________ Questions for your Breast Surgeon and Medical Oncologist: 1. What receptors do my tumor have? 2. What type of treatment do they suggest I will need? 3. May I have a copy of all my pathology reports? 4. Do my receptors already suggest I need chemotherapy? 5. Do my receptors show I will need hormonal therapy? 6. Would I benefit from neoadjuvant chemotherapy? What are Breast Cancer Receptors? Once a breast biopsy is determined to be an invasive by a pathologist under the microscope, they will automatically run at least three more tests on the same tissue to determine what “receptors” are present. Receptors are tiny proteins on the surface of the cells that act like “light switches” that can turn cancer cell growth “on” or “off.” The Estrogen receptor (ER), Progesterone receptor (PR), and HER2 receptor results are incredibly important for you to know and understand. Receptors are different than “grade” and “stage” as outlined in the diagram below. All are different pieces of the breast cancer puzzle that your physicians will assemble to determine the best therapy for you. In the case of receptors, these are key determinants as to whether you will or will not benefit from hormonal therapy (pills) or chemotherapy. The receptors involving a precancerous lesion such as DCIS have different implications and are addressed in our DCIS course. Receptors that suggest Hormonal Therapy Estrogen Receptor Positive (ER+) tumors are always treated with hormonal therapy. Usually these types of medications (pills) are taken for a total of 5 to 10 years. It is still possible that one may need chemotherapy in addition to hormonal therapy. If you are Progesterone Receptor Positive (PR+) then you will likely need hormonal therapy, even if you are ER-. The Estrogen Receptor plays a much more important role in cancer care than the Progesterone Receptor. Receptors that suggest Chemotherapy Determining if you need chemotherapy is a very complex decision process and is primarily driven by your medical oncologist. Your “receptor pattern” is a key piece of information that is known early in your breast cancer journey. In about 30% of patients with an invasive breast cancer, the receptor pattern alone can strongly suggest that chemotherapy will be needed, regardless of what is found at surgery. We list a few of the more common “chemotherapy receptor patterns” below. Many factors, including a large cancer and cancer that is present in the lymph nodes, also point someone towards chemotherapy. Take our video lesson on “Will I Need Chemotherapy“ (here). Often if someone needs chemotherapy, they will likely benefit also from hormonal therapy after chemotherapy if their estrogen receptor is positive. Estrogen Receptor Negative (ER-) tumors do not respond to anti-estrogen oral medications that are essential for treating estrogen receptor positive (ER+) tumors. Quite simply, patients with ER negative tumors will benefit from chemotherapy if they are healthy enough to tolerate it. ER negative tumors are more aggressive cancers, but respond very well to chemotherapy. This includes “triple negative” breast cancers. Progesterone Receptors (PR) play a much smaller role than estrogen or HER2 receptors and are not addressed here. HER2 Receptor Positive (HER2+) tumors are very responsive to chemotherapy when paired with new breakthrough drugs that target these tumors, such as Herceptin and Perjeta. The same holds true if a HER2-positive tumor is also ER positive. Take our “HER2-Positive“ video lesson to learn more (here). HER2-positive tumors are more aggressive cancers, but we now can treat them more effectively with chemotherapy and “targeted immunotherapy” drugs that are designed to destroy HER2-positive cancers. “Triple Negative” (ER-)(PR-)(HER2-) tumors are also fast growing tumors that are usually treated with a specific chemotherapy regimen. These tumors are not responsive to hormonal therapy at all, but are sensitive to chemotherapy. If you have “Triple Negative Breast Cancer“ review our video lesson (here). Take home message: Make sure to ask for a copy of the pathology report from your biopsy. Ask your breast surgeon and medical oncologist to explain to you what your receptors mean regarding your treatment. Sometimes the HER2 receptor results can take up to two weeks to become finalized. Inquire early on with your physicians about your benefit from hormonal therapy and/or chemotherapy.
Просмотров: 74 Breast Cancer School for Patients
Hormonal Therapy for Breast Cancer: We Teach You
 
13:39
We teach you about hormonal therapy for breast cancer. Drugs such as tamoxifen and aromatase inhibitors are key treatment options for most breast cancers. VISIT THE BREAST CANCER SCHOOL FOR PATIENTS: http://www.breastcancercourse.org LIST OF QUESTIONS FOR YOUR DOCTORS: http://www.breastcancercourse.org/breast-health-updates-latest-videos/ FOLLOW US: Facebook: https://www.facebook.com/Breast-Cancer-School-for-Patients-958519147618444/ ________________________________ Questions for your Medical Oncologist: 1. What type of hormonal therapy do you recommend? 2. Will I also benefit from chemotherapy? 3. What are the side effects of hormonal therapy? 4. Will I need 5 or 10 years of these medications? 5. Would the genomic assay Oncotype DX be helpful? 6. What is Hormonal Therapy? Anti-estrogen (estrogen-blocking) medications, prescribed as pills, are incredibly effective at treating certain types of breast cancer. Hormonal therapy is given to about 70 to 80% of women with breast cancer. Chemotherapy, on the other hand, is a more intense cancer treatment that is generally administered intravenously. Most patients will not need chemotherapy. Many women that do need chemotherapy will also benefit from hormonal therapy. These treatment decisions are complex ones with your medical oncologist. You will make better choices when you are well informed before meeting with your medical oncologist. Do my “Receptors” suggest Hormonal Therapy? When the estrogen circulating in your blood stream interacts with a breast cancer that has “Estrogen Receptors” (ER) present on its surface, it tends to flip the ER switch to the “on” or “grow” position for ER Positive tumors. The same can be said to a lesser extent for the “Progesterone Receptor,” if your cancer is found to also be PR positive. Patients with ER+ breast cancers almost always benefit from the anti-estrogen effects of hormonal therapy. These medications can make cancer cells die, or slow down their growth. If a few cancer cells have already spread to other parts of the body, these medications are incredibly effective at preventing these cells from growing and threatening your life in the future. In other words, those who take hormonal therapy for ER+ tumors have a more successful chance at long-term survival when compared to those who do not. About 80% of all breast cancers are ER+. Even if your medical oncologist recommends chemotherapy for you, if your tumor is ER+ you will also benefit from up to 10 years of hormonal therapy after chemotherapy. Hormonal therapy is never given during chemotherapy nor during radiation therapy. What is “Tamoxifen?” Tamoxifen is an anti-estrogen medication (pills) that has been used with great success with ER+ cancers for three decades. It is now the primary hormonal therapy for younger, pre-menopausal women. It is also the primary drug for men with breast cancer. It is used for some post-menopausal women. What are “Aromatase Inhibitors?” Aromatase inhibitors (AIs) are a class of anti-estrogen medications (pills) that have proven to be slightly more effective than Tamoxifen for post-menopausal women. It is not recommended for younger, pre-menopausal women, except in certain circumstances. The three most common versions are Anastrozole (Arimidex), Letrozole (Femara), and Exemestane (Aromasin). What are the side effects of Hormonal Therapy? Side effects vary greatly from one person to the next for both types of hormonal medications. Some have no symptoms at all. Most have very tolerable side effects. Some patients will need to change hormonal therapy medications to find the best balance of cancer benefit versus side effects. Several side effects that are rather common for both tamoxifen and aromatase inhibitors are hot flashes, night sweats, joint pain, and vaginal dryness. Below, we list some of the other specific side effects for both drugs. Tamoxifen Side Effects: Increased risk of uterine (endometrial) cancer Increased risk of developing blood clots Slows normal bone loss in most women (a “good” side effect) Cannot be taken during pregnancy because of risk of birth defects or fetal death Can temporarily induce menopause in pre-menopausal women. Aromatase Inhibitor Side Effects: Can worsen bone loss (osteoporosis) in women Muscle and joint aches and pains Would an “Oncotype DX” assay help me? Patients who have a small, estrogen receptor positive, HER2 receptor negative tumor, and no evidence of cancer in their lymph nodes may benefit from an Oncotype DX genomic assay. This cutting-edge test looks deeper into your cancer cells to better identify people who may also benefit from chemotherapy with ER+ breast cancers. The decision to undergo chemotherapy, in addition to hormonal therapy, is a complicated one. Your medical oncologist uses many factors to help decide if you will benefit from chemotherapy. An Oncotype DX analysis of a portion of your breast cancer tissue can be instrumental in this decision.
Просмотров: 116 Breast Cancer School for Patients
Less Chemotherapy for Breast Cancer: The TAILORx Results
 
12:19
We teach you about the TAILORx clinical trial results and how this information may save many women in the future from chemotherapy. VISIT THE BREAST CANCER SCHOOL FOR PATIENTS: http://www.breastcancercourse.org LIST OF QUESTIONS FOR YOUR DOCTORS: http://www.breastcancercourse.org/breast-health-updates-latest-videos/ FOLLOW US: Facebook: https://www.facebook.com/Breast-Cancer-School-for-Patients-958519147618444/ _________________________________ Questions for your Breast Surgeon and Medical Oncologist: *Do I qualify for an Oncotype DX genomic test? *If so, will you order genomic testing for me? *What if I have an "Intermediate" result? *Do you follow the "TAILORx" trial recommendations? *Would you order a genomic test before I see a medical oncologist? What does the TAILORx Clinical Trial results mean to me? On June 3rd, 2018 the results of the largest breast cancer trial reported results that help us better determine who MAY benefit or MAY NOT benefit from chemotherapy in early stage, favorable breast cancers. The results help patients and physicians better interpret the results from the genomic assay, Oncotype DX, which is commonly used in the United States. The trial concludes that most patients with an "Intermediate Recurrence Score" result may avoid chemotherapy. The results were also released for publication by the New England Journal of Medicine. Journal Article Link: https://www.nejm.org/doi/full/10.1056/NEJMoa1804710 Video Outlining the TAILORx Clinical Trial: https://www.youtube.com/watch?v=orwPgT0ZP_0&t=14s What is a genomic test? These sophisticated tests are performed on a small sample of cancer tissue in appropriate patients with early stage breast cancer. Genomic tests are usually ordered after surgery when the pathology report is finalized. It measures unique aspects of the tumor to determine if a patient will benefit from chemotherapy in addition to hormonal therapy. Such “genomic assays” developed over the last decade are a dramatic advance in breast cancer care. The Oncotype DX assay by Genomic Health Inc. is the most utilized genomic assay of those available in the United States. Who should consider a genomic test? Patients who have small “Estrogen receptor positive” (ER+) and “HER2 receptor negative” (HER2-) tumors and no evidence of cancer in their lymph nodes may benefit from an Oncotype DX assay. The purpose of this test is to better identify people who do and do not benefit from chemotherapy. The decision to undergo chemotherapy is a complicated one. Your medical oncologist will examine multiple factors to help determine if you will benefit from chemotherapy. The NCCN Guidelines, listed in the website links below, outline in much greater detail recommendations for the use of genomic tests. An Oncotype DX test can be instrumental in this decision for many patients. You may qualify for a Genomic Assay if… You have early stage cancer (Stage I or II) Your tumor is Estrogen receptor positive (ER+) Your tumor is Her2 receptor negative (HER2-) No cancer was found in your lymph nodes You are willing to consider having chemotherapy You are healthy enough to undergo chemotherapy How is chemotherapy tailored to patients? Genomic breast cancer tests are a leap forward in our ability to “look inside” breast cancer cells. Sophisticated breast cancer care is based upon the principle of providing maximal benefit from the least toxic therapy. Newly diagnosed breast cancer patients deserve the best information available to decide whether they need chemotherapy. Take our video lesson on “Will I Need Chemotherapy?“ (here) to understand the general concepts. Genomics is a promising and rapidly developing field. Take Home Message: Make sure to ask both your breast surgeon and medical oncologist if a genomic assay might play a role in your treatment decisions. For appropriate patients, these tests should be considered only one piece of the many “pieces of the puzzle” in deciding treatment decisions about chemotherapy and hormonal therapy.
Просмотров: 12383 Breast Cancer School for Patients
Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer
 
03:20
Visit http://www.ecancer.org for more Dr Turner (The Institute of Cancer Research, London, UK) talks to ecancertv at ASCO 2015 about the phase III registration study PALOMA-3, which reports that adding the investigational targeted agent palbociclib to standard hormonal therapy (fulvestrant) more than doubled the duration of disease control, delaying disease progression by roughly five months in women with previously treated, hormone receptor-positive, human epidermal growth factor receptor 2 negative (HR /HER2-) advanced breast cancer.
Просмотров: 63 ecancer
Latest Estrogen Receptor Positive Breast Cancer Information
 
25:15
This power point presentation was given by Dr. Joe Veltmann on August 28th in Guadalajara, Mexico before 200+ medical doctors who heard Dr. Bernard Esquivel speak about pharmacogenomics and Dr. Veltmann about the ER + breast cancer research and how nutrigenomics may play a role in preventing its recurrence.
Просмотров: 1595 Joe Veltmann
Overcoming Resistance in ER+ Breast Cancer
 
03:35
Massimo Cristofanilli, MD, professor of medicine, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, discusses overcoming resistance to endocrine therapy in ER+ breast cancer.
Просмотров: 196 Targeted Oncology
Estrogen Receptor Positive (ER+) Breast Cancer Treatment Landscape across the globe
 
00:26
Avail more information from Sample Brochure of report @ http://tinyurl.com/jm5ndo9 Estrogen Receptor Positive (ER+) Breast Cancer which mainly describes the treatment of breast cancer at different stages. Breast cancer is the condition where the cells of the breast area become tumorous, that is, they undergo unlimited cell division. Both women and men are affected but chances of men being diagnosed with breast cancer are rare. Read Analysis @ http://tinyurl.com/j4wgkdb
Просмотров: 45 Myra Ginsburg
What does Her2 positive mean
 
05:41
There are three very basic tests that will be run on your breast cancer tissue. The first two are ER and PR and these determine whether or not your tumor is hormone responsive. The next is Her2 and it will determine a very important part of your breast cancer treatment. Watch this quick video to get the whole scoop.
Просмотров: 4554 Lisa Schwartz, MD
Updates in ER-Positive Breast Cancer by Debu Tripathy, MD
 
03:27
New therapies for breast cancer are now being based on older therapies such as estrogen blockade. As we understand more about this cancer, we learn that many of the growth pathways are vast networks. If we block one pathway, cancer may find another way to continue growing. Just this year, Afinitor was approved to work along with an aromatase inhibitor to block multiple pathways in advanced estrogen receptor-positive breast cancer. And this may be just the tip of the iceberg. For more on ER-positive breast cancer updates, see the Fall 2012 issue of CURE magazine coming out in September!
Просмотров: 416 curetoday
Treatment Options for Early Stage Breast Cancer
 
02:31
http://www.beetmedicine.tv/2009/06/treatment-options-for-early-stage-breast-cancer.html Hormone therapy is used in all stages of estrogen receptor positive breast cancer. The success of five years of Tamoxifen in post menopausal women has been augmented by the addition of Aromatase inhibitors. Dr. Rugo describes the randomized clinical trials designed to determine the duration and sequencing of hormones and the different approaches required in pre and post menopausal women. Also, the emerging role of biphosphonates, a non-hormonal, non-chemotherapy approach to strengthening bone and preventing metastases. Interviewee: Hope S. Rugo, MD, Clinical Professor of Medicine; Director, Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center Hope Rugo
Просмотров: 2867 BeetMedicineTV
The PATINA Breast Cancer Clinical Trial
 
01:25
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer. This study is open to people diagnosed with hormone receptor (HR) positive, Human Epidermal Growth Factor Receptor 2 (HER-2) positive metastatic breast cancer. Metastatic breast cancer is cancer that has spread from the primary site (breast) to other parts of the body (distant sites). HER2 is a receptor which is known to promote cancer growth when present in levels above normal. Despite significant improvements in the treatment of early-stage breast cancer, approximately 30% of women experience metastatic disease relapse. Development of therapies targeting the HER2 receptor has dramatically improved patient outcomes. ---------------------------------------------------------------- Breast Cancer Trials is a group of world-leading breast cancer doctors and researchers based in Australia and New Zealand committed to exploring and finding better treatments for people affected by breast cancer through clinical trials research. Please like this video then visit www.breastcancertrials.org.au to find out more about our current breast cancer clinical trials that may be suitable for you, and ways in which you can help support breast cancer research. ---------------------------------------------------------------- SUBSCRIBE TO OUR YOUTUBE CHANNEL https://www.youtube.com/channel/UCoVl5WNMfqrJSpggZVzsa6g?sub_confirmation=1 LET'S CONNECT Email ►enquiries@bctrials.org.au Tel 1800 423 444 WWW ► http://www.breastcancertrials.org.au Linkedin ► https://www.linkedin.com/company/5057154 Twitter ► https://twitter.com/BCTrialsANZ Facebook ► https://www.facebook.com/breastcancertrials Instagram ► https://instagram.com/breastcancertrials
Просмотров: 146 Breast Cancer Trials
Treatment of HER2-Positive Breast Cancer
 
11:07
In this segment, Joyce O’Shaughnessy, MD; Debu Tripathy, MD; and Edith Perez, MD, review treatment options of human epidermal growth factor receptor (HER)-2-positive breast cancer.
Просмотров: 2810 OncLiveTV
Dr. Callahan on Endocrine Therapy in Patients With ER-Positive Breast Cancer
 
01:54
Rena D. Callahan, MD, assistant clinical professor of medicine, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the use of endocrine therapy in patients with estrogen receptor (ER)-positive breast cancer.
Просмотров: 38 OncLiveTV
The significance of fulvestrant for hormone receptor-positive advanced breast cancer
 
01:18
Matthew Ellis, MB, BChir, PhD, FRCP of Baylor College of Medicine, Houston, TX discusses the significance of fulvestrant for hormone receptor-positive advanced breast cancer. Metastatic breast cancer and in particular hormone receptor-positive advanced breast cancer, is not an immediate death sentence as Prof. Ellis explains. Many patients do well with different endocrine manipulations and with fulvestrant, we have a potential drug to extend the durability of these initial endocrine responses; this is a key result of the FALCON trial (NCT01602380). He explains that the patients responding to fulvestrant had better quality responses, which means that they are not in need of more complicated therapies or chemotherapy. Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.
Просмотров: 47 VJOncology
ASCO 2016 Metastatic Breast Cancer News: Estrogen Receptor Positive
 
19:23
On June 11, 2016, Lurie Cancer Center's Dr. William Gradishar offered a summary of ASCO 2016 metastatic breast cancer highlights at a special MBC program put on by the Silver Lining Foundation. Dr. Gradishar specifically addressed estrogen receptor positive developments; Loyola University Medical Center's Dr. Kathy Albain addressed triple negative and HER2 positive news. (Unfortunately we only have a video of Dr. Gradishar's remarks.)
Просмотров: 1748 Metastatic Breast Cancer Network (MBCN)